| Dr John Elbert Greene, MD | |
|
311 N Clyde Morris Blvd Ste 480, Daytona Beach, FL 32114-2766 | |
| (386) 425-4199 | |
| (386) 425-4680 |
| Full Name | Dr John Elbert Greene |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 58 Years |
| Location | 311 N Clyde Morris Blvd Ste 480, Daytona Beach, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932148509 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | ME12921 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Halifax Health Medical Center | Daytona beach, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Halifax Healthcare Systems Inc | 1254238090 | 278 |
News Archive
National charity Brainwave, which provides home based therapy programmes for children with cerebral palsy and other conditions such as development delay, is opening a third Centre in Birchwood, Warrington to cope with the increasing demand for its services.
The importance of the research and clinical care work at Joslin Diabetes Center in Boston has been affirmed by a report from the Centers for Disease Control and Prevention predicting that one-third of all U.S. adults will have diabetes by 2050 if current trends continue.
One in five older people who drink alcohol are consuming it at unsafe levels - over 21 units of alcohol for men and 14 units for women each week - according to a study by King's College London. The research in inner-city London, published in BMJ Open, found these unsafe older drinkers are more likely to be of higher socioeconomic status.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.
Researchers at Progenra, Inc. announce the advanced online publication of the article "Selective Dual Inhibitors of the Cancer-related Deubiquitylating Proteases USP7 and USP47." The new article presents evidence of a therapeutic benefit resulting from dual inhibition of USP7 and a related enzyme, USP47.
› Verified 1 days ago
| Entity Name | Halifax Healthcare Systems Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245283530 PECOS PAC ID: 1254238090 Enrollment ID: O20031218000443 |
News Archive
National charity Brainwave, which provides home based therapy programmes for children with cerebral palsy and other conditions such as development delay, is opening a third Centre in Birchwood, Warrington to cope with the increasing demand for its services.
The importance of the research and clinical care work at Joslin Diabetes Center in Boston has been affirmed by a report from the Centers for Disease Control and Prevention predicting that one-third of all U.S. adults will have diabetes by 2050 if current trends continue.
One in five older people who drink alcohol are consuming it at unsafe levels - over 21 units of alcohol for men and 14 units for women each week - according to a study by King's College London. The research in inner-city London, published in BMJ Open, found these unsafe older drinkers are more likely to be of higher socioeconomic status.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.
Researchers at Progenra, Inc. announce the advanced online publication of the article "Selective Dual Inhibitors of the Cancer-related Deubiquitylating Proteases USP7 and USP47." The new article presents evidence of a therapeutic benefit resulting from dual inhibition of USP7 and a related enzyme, USP47.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Elbert Greene, MD 303 N Clyde Morris Blvd, Daytona Beach, FL 32114-2709 Ph: (386) 226-4590 | Dr John Elbert Greene, MD 311 N Clyde Morris Blvd Ste 480, Daytona Beach, FL 32114-2766 Ph: (386) 425-4199 |
News Archive
National charity Brainwave, which provides home based therapy programmes for children with cerebral palsy and other conditions such as development delay, is opening a third Centre in Birchwood, Warrington to cope with the increasing demand for its services.
The importance of the research and clinical care work at Joslin Diabetes Center in Boston has been affirmed by a report from the Centers for Disease Control and Prevention predicting that one-third of all U.S. adults will have diabetes by 2050 if current trends continue.
One in five older people who drink alcohol are consuming it at unsafe levels - over 21 units of alcohol for men and 14 units for women each week - according to a study by King's College London. The research in inner-city London, published in BMJ Open, found these unsafe older drinkers are more likely to be of higher socioeconomic status.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.
Researchers at Progenra, Inc. announce the advanced online publication of the article "Selective Dual Inhibitors of the Cancer-related Deubiquitylating Proteases USP7 and USP47." The new article presents evidence of a therapeutic benefit resulting from dual inhibition of USP7 and a related enzyme, USP47.
› Verified 1 days ago
Dr. Bennett Peter Scaglia, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 311 N Clyde Morris Blvd, Suite 360, Daytona Beach, FL 32114 Phone: 386-254-4199 Fax: 386-947-4680 | |
Shawn Wayne Thomas, D.O. Urology Medicare: Accepting Medicare Assignments Practice Location: 311 N Clyde Morris Blvd Ste 360, Daytona Beach, FL 32114 Phone: 386-254-4199 Fax: 386-947-4680 | |
Dr. Sean Tirney, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1925 S Atlantic Ave, Suite #609, Daytona Beach, FL 32118 Phone: 386-747-4240 | |
Michael Doughney Dineen, MD Urology Medicare: Medicare Enrolled Practice Location: 545 Health Blvd, Daytona Beach, FL 32114 Phone: 386-239-8500 | |
Benjamin T Brown, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 545 Health Blvd, Daytona Beach, FL 32114 Phone: 386-239-8500 | |
Dr. Charles E Womack, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 303 N Clyde Morris Blvd, Daytona Beach, FL 32114 Phone: 386-254-4199 Fax: 386-947-4680 | |
Dr. Tony L Cantwell, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 545 Health Blvd, Daytona Beach, FL 32114 Phone: 386-239-8500 |